Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — J.P. Morgan 2026 Healthcare Conference
26 slides from Vir Biotechnology's conference presentation, Jan 12, 2026
Slide 1: J.P. Morgan 2026 Healthcare Conference
January 14, 2026 J.P. Morgan 2026 Healthcare Conference 2026 Vir Biotechnology, Inc. 1
Slide 2: Legal disclaimer
Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of Vir Biotechnology's CH
Slide 3: Powering the immune system to transform lives
3 POWERING THE IMMUNE SYSTEM TO TRANSFORM LIVES 2026 Vir Biotechnology, Inc.
Slide 4: Our path to delivering transformational therapies
Our path to delivering transformational therapies to people living with devastating diseases Commercializing our chronic hepatitis delta (CHD) combination therapy will drive near-term revenue sustainability Aiming Vir Bio's discovery engine at developing a robust pipeline of cancer immunotherapies c
Slide 5: Our clinical programs address large and growing unmet needs
Our clinical programs address large and growing unmet needs Infectious Disease Oncology – Solid Tumors 2032 prevalence estimate for U.S., EU4 and UK EGFR VIR-5525 Phase 1 Drug-Treated Patients3 431K mNSCLC 69K mHNSCC 271K mCRC HER2 VIR-5818 Phase 1 Drug-Treated Patients3 27K HER2+ mUC 11K HER2+ mCRC
Slide 6: Our path: Chronic Hepatitis Delta (CHD)
Our path to delivering transformational therapies to people living with devastating diseases: Chronic Hepatitis Delta (CHD) Commercializing our chronic hepatitis delta (CHD) combination therapy will drive near-term revenue sustainability Accelerating our masked T-cell engager (TCE) immunotherapy por
Slide 7: CHD: devastating liver disease, significantly underserved with high mortality
CHD: devastating liver disease, significantly underserved with high mortality 72026 Vir Biotechnology, Inc. 5 years Average progression to cirrhosis and liver failure2 >50% Liver-related death in 10 years1 Risk of liver cancer (HCC) vs. HBV3 3X 1 Negro F. (2023). Hepatitis D: A Review. JAMA. 330(24)
Slide 8: Our CHD combination regimen is potentially best-in-class
Neutralization of HDV & HBV virions (tobevibart) Degradation of HBV RNA & reduction of HBsAg production (elebsiran) tobevibart (mAb) + elebsiran (siRNA) combination therapy key differentiators Our CHD combination regimen is potentially best-in-class Two complementary MOAs & highly differentiated tar
Slide 9: Ph2 SOLSTICE trial design
Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD Study design: tobevibart + elebsiran Q4W and tobevibart Q2W Primary Endpoints: • Proportion of participants with HDV RNA <LOD or ≥2 log10 IU/mL reduction (virologic response) and ALT <ULN (ALT response) at Week 24 • TEAEs and seri
Slide 10: SOLSTICE: undetectable HDV RNA in 88% at Week 96
0 24 48 72 96 0 20 40 60 80 100 % o f p ar tic ip an ts w ith H D V R N A T ND N=32 N=33 32 33 32 33 31 32 24 24 Study Week Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD Monthly combo therapy achieved undetectable HDV RNA in 88% of patients that reached Week 96 vs. 46% with m
Slide 11: SOLSTICE: HBsAg reductions with combination therapy
Ph2 SOLSTICE trial evaluating potential best-in-class therapy for CHD ~90% of participants receiving tobevibart + elebsiran achieved very low HBsAg values by Week 24 and maintain suppression 112026 Vir Biotechnology, Inc. Hepatitis delta virus (HDV) requires serum HBV surface antigen (HBsAg) to repl
Slide 12: SOLSTICE results show robust and durable efficacy
Ph2 SOLSTICE results to-date show monthly tobevibart + elebsiran combo is well tolerated with robust and durable efficacy Summary of available data through Week 96 122026 Vir Biotechnology, Inc. CHD Monthly combination therapy achieves and maintains HDV RNA TND in 88% of participants who reached Wee
Slide 13: Registrational ECLIPSE program progressing ahead of schedule
*Defined as failure to achieve HDV RNA < 500 IU/mL with bulevirtide ALT: alanine aminotransferase; HDV: hepatitis D virus; TND: target not detected HDV RNA TND = undetectable HDV RNA ECLIPSE ClinicalTrials.gov Identifiers: ECLIPSE 1 NCT06903338, ECLIPSE 2 NCT07128550, ECLIPSE 3 NCT07142811 Registrat
Slide 14: Collaboration with Norgine for Europe and ANZ
Accelerating access to our CHD regimen to patients in Europe and ANZ through collaboration with Norgine 142026 Vir Biotechnology, Inc. • Norgine is a leading European-focused specialty pharma with market-leading products in hepatology/GI, rare disease and pediatric oncology • Exclusive commercial li
Slide 15: Our path: cancer immunotherapy
Our path to delivering transformational therapies to people living with devastating diseases: cancer immunotherapy Commercializing our chronic hepatitis delta (CHD) combination therapy will drive near-term revenue sustainability Accelerating our masked T-cell engager (TCE) immunotherapy portfolio of
Slide 16: Masked TCEs powered by the PRO-XTEN platform
T-cell engagers (TCEs) are a powerful modality in cancer therapy Our masked TCEs act like Trojan Horses, powered by the PRO-XTEN® platform 16 Clinically validated, used on a blockbuster drug for hemophilia A2 2026 Vir Biotechnology, Inc. TCE Designed to reduce toxicity, enabling higher dosing and wi
Slide 17: Our pipeline of TCEs enabled by PRO-XTEN masking
Our unique pipeline of TCEs is enabled by the PRO-XTEN® masking platform Allows our TCEs to overcome challenges of unmasked and single-masked TCEs 172026 Vir Biotechnology, Inc. TCE Tumor-binding domain Variable region binds tumor-associated antigen T-cell-binding domain Variable region binds CD3 to
Slide 18: Our clinical pipeline of masked TCEs
Our clinical pipeline of masked TCEs reflects the promise of the PRO-XTEN® platform • The only dual-masked PSMA-targeted TCE • Phase 1 study (n=18) oEfficacy: 100% PSA decline, 58% PSA50 responses at early doses2 oSafety: no Gr3 CRS, and very low levels of ≥Gr3 TRAEs • Next steps: continue Q3W monot
Slide 19: VIR-5500 PSMA-targeted masked TCE early dose response
VIR-5500 PSMA-targeted masked TCE has shown strong early dose response and promising safety profile in late-line mCRPC 192026 Vir Biotechnology, Inc. Strong PSA50 responses and favorable safety profile at early dose cohorts1 in Phase 1 • 100% (12/12) response across all 12 patients • 58% (7/12) PSA5
Slide 20: VIR-5500 data at ASCO-GU in February
VIR-5500 data to be presented at ASCO Genitourinary Cancers Symposium (ASCO-GU) in February 202026 Vir Biotechnology, Inc. Safety • Weekly and Q3W dosing in late-line monotherapy dose escalation • Detailed safety data, including CRS rates and treatment-related adverse events Next steps • Plans for e
Slide 21: Our path: Vir Bio's discovery engine
Our path to delivering transformational therapies to people living with devastating diseases: Vir Bio's discovery engine Commercializing our chronic hepatitis delta (CHD) combination therapy will drive near-term revenue sustainability Accelerating our masked T-cell engager (TCE) immunotherapy portfo
Slide 22: Vir Bio discovery engine fuels next generation of therapeutics
World class protein engineering, antibody discovery dAIsY AI/ML for antibody optimization Exclusive PRO-XTEN® universal masking technology We’ve developed a powerful Vir Bio discovery engine to fuel the next generation of therapeutics World clas protein engine ring, antibody / TCE discovery dAIsY AI
Slide 23: Delivering a differentiated pipeline in oncology and infectious disease
Delivering a differentiated pipeline in oncology and infectious disease Driving near-term and long-term value creation 232026 Vir Biotechnology, Inc. 1 Masked TCEs licensed from Sanofi 2 In collaboration with the Gates Foundation ARPIs: androgen receptor pathway inhibitors; EGFR: epidermal growth fa
Slide 24: Upcoming clinical milestones
Upcoming clinical milestones PROGRAM DRUG CANDIDATES REGIMEN CATALYST TIMING Hepatitis Delta tobevibart (mAb) + elebsiran (siRNA) SOLSTICE: 72 & (partial) 96-week data ECLIPSE 1: topline data ECLIPSE 2: topline data ECLIPSE 3: topline data Jan’26 4Q’26 1Q’27 1Q’27 PSMA-Expressing Prostate Cancer VIR
Slide 25: Our strategic approach creates short and long-term value drivers
Our strategic approach creates short and long-term value drivers chronic hepatitis delta ECLIPSE 1 topline data in 4Q26 ECLIPSE 2 & 3 topline data in 1Q27 universal masked TCEs VIR-5500 PSMA data update at ASCO GU in 1Q26 VIR-5818 HER2 data update in 2H26 discovery engine Discovery engine driving fu
Slide 26: Patients are waiting
PATIENTS ARE WAITING 2026 Vir Biotechnology, Inc. 2026 Vir Biotechnology, Inc. 26
Vir Biotechnology — J.P. Morgan 2026 Healthcare Conference on 6ix